History
  • No items yet
midpage
585 U.S. 33
SCOTUS
2018
Read the full case

Background

  • U.S. purchasers sued Chinese vitamin C manufacturers alleging a price‑fixing cartel in violation of §1 of the Sherman Act.
  • Chinese defendants moved to dismiss, arguing Chinese law compelled the pricing scheme (invoking foreign sovereign compulsion/act‑of‑state and comity).
  • The Chinese Ministry of Commerce filed an amicus brief asserting the Ministry (and a Chamber subcommittee it supervised) required coordinated export prices/quotas, characterizing the conduct as a government‑mandated pricing regime.
  • Plaintiffs produced contrary materials: no specific written Chinese law was cited by the Ministry, a Chamber announcement describing a voluntary self‑regulation, expert testimony, and China’s WTO statement that export administration of vitamin C ended in 2002.
  • The District Court denied dismissal and later denied summary judgment, the case went to a jury which found for plaintiffs; the Second Circuit reversed, holding federal courts must defer to a foreign government’s reasonable statement about its own law.
  • The Supreme Court vacated and remanded: foreign governments’ official statements deserve respectful consideration but are not conclusive under Fed. R. Civ. P. 44.1; courts may consider any relevant material and weigh submissions in context.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether a foreign government’s official statement about its law is conclusive in U.S. courts under Rule 44.1 Ministry’s statement is not binding; courts should examine all evidence and materials A foreign government’s reasonable characterization of its law should be binding on U.S. courts A foreign government’s submission merits respectful consideration but is not conclusive; courts may consult any relevant sources and weigh the submission under the circumstances
Whether Chinese law compelled the defendants’ price‑fixing (so as to shield them from Sherman Act liability) Chinese law did not mandate the agreements; evidence supported voluntariness Chinese Ministry’s amicus brief and defendant experts said the law/regulatory scheme compelled pricing Court did not decide ultimate meaning of Chinese law; remanded so lower courts may weigh all materials rather than treat Ministry brief as dispositive
Proper standard of review for foreign‑law determinations De novo review considering all relevant materials Deference to foreign government statements should resolve question at early stage Foreign‑law determination is a question of law reviewed de novo; Rule 44.1 allows courts to consider any relevant material
Whether Second Circuit’s rule requiring deference when a foreign government’s statement is "reasonable" is correct That rigid rule improperly forecloses courts from weighing other evidence The Second Circuit held U.S. courts are bound to defer to reasonable official foreign statements Rejected the Second Circuit’s binding‑if‑reasonable rule as inconsistent with Rule 44.1 and international/comity practice

Key Cases Cited

  • Talbot v. Seeman, 1 Cranch 1 (establishing common‑law rule that foreign law was treated as fact)
  • United States v. Pink, 315 U.S. 203 (pre‑Rule 44.1 decision where an official diplomatic declaration was treated as conclusive under special circumstances)
  • Société Nationale Industrielle Aérospatiale v. United States Dist. Court for Southern Dist. of Iowa, 482 U.S. 522 (international comity considerations in judicial proceedings)
  • Wainwright v. Goode, 464 U.S. 78 (state‑court decisions of the highest court are binding on federal courts)
  • Arizonans for Official English v. Arizona, 520 U.S. 43 (States’ attorneys general views get respectful consideration but are not controlling)
Read the full case

Case Details

Case Name: Animal Science Products, Inc. v. Hebei Welcome Pharmaceutical Co.
Court Name: Supreme Court of the United States
Date Published: Jun 14, 2018
Citations: 585 U.S. 33; 138 S. Ct. 1865; 201 L. Ed. 2d 225; 2018 U.S. LEXIS 3684; 16-1220
Docket Number: 16-1220
Court Abbreviation: SCOTUS
Log In
    Animal Science Products, Inc. v. Hebei Welcome Pharmaceutical Co., 585 U.S. 33